Clinical Trial Update: High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating high-dose aflibercept (Eylea) for outcomes in Proliferative Diabetic Retinopathy. The study is currently active but not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Diabetic Retinopathy

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Edward Wood, MD | Conditions: Proliferative Diabetic Retinopathy (PDR) | Phase 4 | Status: ACTIVE_NOT_RECRUITING